Glucuronidation enzymes, genes and psychiatry

International Journal of Neuropsychopharmacology

Volumn 6, Issue 1, 2003, Pages 57-72

  De Leon, Jose ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b EASTERN STATE HOSPITAL   (United States)

Author keywords

Glucuronidation; Metabolism; Polymorphisms; Psychiatry; UDP glucuronosyltransferases

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMITRIPTYLINE; ANDROGEN; ANDROSTERONE; ANTICONVULSIVE AGENT; BILE ACID; BILIRUBIN; BUPRENORPHINE; CATECHOL ESTROGEN; CLOFIBRATE; CLOZAPINE; CYPROHEPTADINE; CYTOCHROME P450; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; ISOENZYME; LORAZEPAM; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; OPIATE; OXAZEPAM; PARACETAMOL; PREGNANEDIOL; PROMETHAZINE; SEROTONIN; SEX HORMONE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BRAIN TISSUE; CHROMOSOME 2; CHROMOSOME 6; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; FETUS DEVELOPMENT; GENE; GLUCURONIDATION; HUMAN; NEUROPROTECTION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEQUENCE HOMOLOGY;

ANIMALS; GLUCURONOSYLTRANSFERASE; HUMANS; LORAZEPAM; OXAZEPAM; POLYMORPHISM, GENETIC; PSYCHIATRY; SEROTONIN;

EID: 0037345011     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003249     Document Type: Review

References (133)

1. Albert C, Vallee M, Beaudry G, Belanger A, Hum DW (1999). The monkey and human uridine diphosphateglucuronosyltransferase UGT1A9, expressed in steroid target issues, are estrogen-conjugating enzymes. Endocrinology 140, 3292-3302.
2. Alvan G, Bertilsson L, Dahl ML, Ingelman-Sundberg, Sjoqvist F (2001). Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metabolism and Disposition 4, 580-585.
3. Anderson GD (1998). A mechanistic approach to antiepileptic drug interactions. Annals of Pharmacotherapy 32, 554-563.
4. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasewaga Y (2002). Polymorphisms of UDPglucuronosyltransferase and pharmacokinetics of irinotecan. Therapeutic Drug Monitoring 24, 111-116.
5. Armstrong M, Daly AK, Blennerhassett R, Ferier N, Idle JR (1997). Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. British Journal of Psychiatry 170, 23-26.
6. Arthur H, Dahl ML, Siwers B, Sjoqvist F (1995). Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. Journal of Clinical Psychopharmacology 15, 211-216.
7. Baruzzi A, Albani F, Riva R (1994). Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35 (Suppl. 3), S14-S19.
8. Belanger A, Hum DW, Beaulieu M, Levesque E, Guillemette C, Tchernof A, Belanger G, Turgeon D, Dubois S (1998). Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. Journal of Steroid Biochemistry and Molecular Biology 65, 301-310.
9. Benowitz NL, Jacob P (1997). Individual differences in nicotine kinetics and metabolism in humans. NIDA Research Monograph 173, 48-64.
10. Benowitz NL, Jacob P (2000). Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clinical Pharmacology and Therapeutics 67, 653-659.
11. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P (1999). Ethnic differences in N-glucuronidation of nicotine and cotinine. Journal of Pharmacology and Experimental Therapeutics 291, 1196-1203.
12. Bernus I, Dickinson RG, Hooper WD, Eadie MJ (1997). The mechanism of the carbamazepine-valproate interaction in humans. British Journal of Clinical Pharmacology 44, 21-27.
13. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985). Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Therapeutic Drug Monitoring 7, 478-480.
14. Bertilsson L, Mellstrom B, Sjoqvist F, Martensson B, Asberg M (1981). Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 340, 560-561.
15. Bertz RJ, Granneman GR (1997). Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics 32, 210-258.
16. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO (2000). Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10, 679-685.
17. Bock KW, Gschaidmeier H, Heel H, Lehmkoster T, Munzel PA, Bock-Hennig BS (1999). Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Drug Metabolism Review 31, 411-422.
18. Bork J, Rogers T, Wedlund P, de Leon J (1999). A pilot study of risperidone metabolism: The role of cytochrome P450 2D6 and 3A. Journal of Clinical Psychiatry 60, 469-476.
19. Breyer-Pfaff U, Becher B, Nusser R, Nill K, Baier-Weber B, Zaunbrecher D (1990). Quaternary N-glucuronides of 10-hydroxylated amitriptyline metabolites in human urine. Xenobiotica 20, 727-738.
20. Breyer-Pfaff U, Wachsmuth H (2001). Tertiary N-glucuronides of clozapine and its metabolite desmethlyclozapine in patient urine. Drug Metabolism and Disposition 29, 1343-1349.
21. Britto M, Wedlund P (1992). Cytochrome P450 in the brain: potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metabolism and Disposition 20, 446-450.
22. Burchell B, Brierley C, Rance D (1995). Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sciences 57, 1819-1831.
23. Burchell B, Brierley CH, Monaghan G, Clarke DJ (1998). The structure and function of the UDP-glucuronosyltransferase gene family. Advances in Pharmacology 42, 335-338.
24. Burchell B, Coughtrie MW (1997). Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environmental Health Perspective 105, 739-747.
25. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B (2000). Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicology Letters 112-113, 333-340.
26. Byrd GD, Caldwell WS, Bhatti BS, Ravard A, Crooks PA (2000). Direct determination of nicotine-N-glucuronide in human biological samples. Drug Metabolism and Drug Interactions 16, 1-17.
27. Caldwell WS, Greene JM, Byrd GD, Chang KM, Uhrig MS, deBethizy JD, Crooks PA, Bhatti BS, Riggs RM (1992). Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. Chemical Research and Toxicology 5, 280-285.
28. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999). Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 37, 177-193.
29. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ (1998). Racial and ethnic differences in serum cotinine levels of cigarette smokers. Journal of the American Medical Association 280, 135-139.
30. Cervilla JA, Russ C, Holmes C, Aitchison K, Smith CAD, Powell J (1999). CYP2D6 polymorphism in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E ε4 effect modification. Biological Psychiatry 45, 426-429.
31. Chen S, Chou WH, Blouin RA, Mao Z, Meek Q, Neill J (1986). The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clinical Pharmacology and Therapeutics 60, 522-534.
32. Cheng Z, Rios GR, King CD, Coffman BL, Green MD, Mojarrabi B, Mackenzie PI, Tephly (1998). Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicological Sciences 45, 52-57.
33. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder T, Liu WW, Teiling C, Wedlund PJ (2000). An extension of a pilot study: impact from the cytochrome P450-2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. Journal of Clinical Psychopharmacology 20, 246-252.
34. Christrup LL (1997). Morphine metabolites. Acta Anaesthesiologica Scandinavica 41, 116-122.
35. Cichon S, Nothen MM, Rietschel M, Propping P (2000). Pharmacogenetics of schizophrenia. American Journal of Medical Genetics (Seminary of Medical Genetics) 97, 98-106.
36. Clarke DJ, Burchell B (1994). Conjugation-deconjugation reactions in drug metabolism and toxicity. Handbook of Experimental Pharmacology 112, 3-43.
37. Coffman BL, King CD, Rios GR, Tephly TR (1998). The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metabolism and Disposition 26, 73-77.
38. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. Journal of Pharmacology and Experimental Therapeutics 299, 998-1006.
39. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ (1998). Pilot study of the cytochrome P-450 2D6 genotype in a psychiatric state hospital. American Journal of Psychiatry 155, 1278-1280.
40. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh AO, Dwoskin LP, Crooks P (2002). Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke. Journal of Clinical Psychopharmacology 22, 496-501.
41. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh O, Dwoskin LP, Crooks P (In Press). Plasma cotinine, 3′-hydroxycotinine and their glucuronides in Caucasian and African American smokers [Letter]. Journal of Clinical Psychopharmacology.
42. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999). Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clinical Pharmacokinetics 36, 439-452.
43. Editorial comment (1997). New research horizons. Science 278, 2039.
44. Ethell BT, Anderson GD, Beaumont K, Rance DJ, Burchell B (1998). A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity. Analytical Biochemistry 255, 142-147.
45. Findlay KA, Kaptein E, Visser TJ, Burchell B (2000). Characterization of the uridine diphosphateglucuronosyltransferase catalyzing thyroid hormone glucuronidation in man. Journal of Clinical Endocrinology and Metabolism 85, 2879-2883.
46. Flockhart DA, Webb J (1998). Blue-chip technology. Lancet 352, 2900.
47. Fuhr U (2000). Induction of drug metabolism enzymes: pharmacokinetic and toxicological consequences in humans. Clinical Pharmacokinetics 38, 493-504.
48. Ghosheh OA, Browne D, Rogers T, de Leon J, Dwoskin LP, Crooks PA (2000). A simple high performance liquid chromatographic method for the quantification of total cotinine, total 3′-hydroxicotinine and caffeine in the plasma of smokers. Journal of Pharmaceutical and Biomedical Analysis 23, 543-549.
49. Ghosheh O, Hawes EM (2002). N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. Drug Metabolism and Disposition 30, 991-996.
50. Golovinsky E, Naydenova Z, Grancharov K (1998). UDP-Glucuronosyltransferase inhibitors. European Journal of Drug Metabolism and Pharmacokinetics 23, 453-456.
51. Green MD, King CD, Mojarrabi B, Mackenzie P, Tephly TR (1998). Glucuronidation of amine and other xenobiotics catalyzed by expressed human UDP-glucuronosyl-transferase 1A3. Drug Metabolism and Disposition 26, 507-512.
52. Green MD, Tephly TR (1998). Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyl-transferase proteins. Drug Metabolism and Disposition 26, 860-867.
53. Gueraud F, Paris A (1998). Glucuronidation: a dual control. General Pharmacology 31, 683-688.
54. Hachad H, Ragueneau-Majlessi I, Levy RH (2002). New antiepileptic drugs: review on drug interactions. Therapeutic Drug Monitoring 24, 91-103.
55. Haffen E, Vandel P, Bonin B, Vandel S (1999). Citalopram pharmacokinetic interaction with cloimipramine. UDP- glucuronosyltransferase inhibition? A case report [Letter]. Therapie 54, 768-770.
56. Hagg S, Spigset O, Lakso HA, Dahlqvist R (2001). Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. European Journal of Clinical Pharmacology 57, 493-497.
57. +-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metabolism and Disposition 26, 830-837.
58. Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, Skorpen F (2002). Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. European Journal of Pharmacology 58, 353-356.
59. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metabolism and Disposition 29, 686-692.
60. Iwahashi K (1994). CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biological Psychiatry 36, 781-782.
61. Iyer L (1999). Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Molecular Diagnosis 4, 327-333.
62. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ (1999). Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronication in human liver tissue with UGT1A1 promoter polymorphism. Clinical Pharmacology and Therapeutics 65, 576-582.
63. Iyer L, Das S, Janisch L, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics Journal 2, 43-47.
64. Kassahun K, Mattiuz E, Franklin R, Gillespie T (1998). Olanzapine 10-N-glucuronide: a tertiary N-glucuronide unique to humans. Drug Metabolism and Disposition 26, 848-855.
65. Kauffman KR, Gerner R (1998). Lamotrigine toxicity secondary to sertraline. Seizure 7, 163-165.
66. Kawanishi Y, Tachikawa H, Suzuki T (2000). Pharmacogenomics in schizophrenia. European Journal of Pharmacology 40, 727-741.
67. King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, Tephly TR (1996). The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Archives of Biochemistry and Biophysics 332, 92-100.
68. King CD, Rios GR, Assouline JA, Tephly TR (1999). Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytriptamine as a substrate. Archives of Biochemistry and Biophysics 365, 156-162.
69. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specfic dosages. Acta Psychiatrica Scandinavica 104, 173-192.
70. Krau RP, Diaz P, McEachran A (1996/1997). Managing rapid metabolizers of antidepressants. Depression and Anxiety 4, 320-327.
71. Kroemer H, Klotz U (1992). Glucuronidation of drugs: a re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clinical Pharmacokinetics 23, 292-310.
72. Kudo S, Ishizaki T (1999). Pharmacokinetics of haloperidol: an update. Clinical Pharmacokinetics 37, 435-456.
73. Lampe JW, Bigler J, Bush AC, Potter JD (2000). Prevalence of polymorphisms in the human UDP-glucuronosyl-transferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiology, Biomarkers and Prevention 9, 329-333.
74. Leakey JEA, Hume R, Burchell B (1987). Development of multiple activities of UDP-glucuronosyltransferase in human liver. Biochemical Journal 245, 859-861.
75. Lee SA, Lee JK, Heo K (2002). Coma probably induced by lorazepam-valproate interaction. Seizure 11, 124-125.
76. Lertola J (1999). Deciphering the code and what might come from it. Time (8 November), 68-69.
77. Licht RW, Olesen OV, Friis P, Lausten T (2000). Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine [Letter]. Journal of Clinical Psychopharmacology 20, 110-112.
78. Linnet K, Olesen OV (2001). In vitro glucuronidation of the antipsychotic drug olanzapine [Abstract]. Drug Metabolism Review 33 (Suppl. 1), 126.
79. Linnet K, Olesen OV (2002). Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine co-medication. Therapeutic Drug Monitoring 24, 512-517.
80. Liston HL, Markowitz JS, DeVane L (2001). Drug glucuronidation in clinical psychopharmacology. Journal of Clinical Psychopharmacology 21, 500-515.
81. Lucas RA, Gilfillan DJ, Bergstrom RF (1998). A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. European Journal of Clinical Pharmacology 54, 639-643.
82. Luo H, Hawes EM, McKay G, Korchinski ED, Midha KK (1995). N(+)-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica 25, 291-301.
83. +-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biological Mass Spectrometry 23, 147-148.
84. Mackenzie PI, Miners JO, McKinnon RA (2000). Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clinical Chemistry and Laboratory Medicine 38, 889-892.
85. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7, 255-269.
86. Malhotra AK (2001). Pharmacogenomics and schizophrenia: clinical implications. Pharmacogenomics 1, 109-114.
87. Markowitz JS, Devane CL, Liston HL, Boulton DW, Risch SC (2002). The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clinical Pharmacology and Therapeutics 71, 30-38.
88. Meyer JW, Woggon B, Küpfer A (1988). Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine - a retrospective study. Pharmacopsychiatry 21, 365-366.
89. Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Ono S, Kaneko S, Otani K, Inoue Y (2000). Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Therapeutic Drug Monitoring 22, 245-249.
90. Miners JO, Mackenzie PI (1991). Drug glucuronidation in humans. Pharmacology and Therapeutics 51, 347-369.
91. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G (1991). Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Research Review 16, 65-82.
92. Munzel PA, Schmohl S, Heel H, Kalberer K, Bock-Hennig BS, Bock KW (1999). Induction of human UDP glucuronosyl-transferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metabolism and Disposition 27, 569-573.
93. Myaoka T, Seno H, Itoga M, Ijima M, Inagaki T, Horiguchi J (2000b). Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). Journal of Clinical Psychiatry 61, 868-871.
94. Myaoka T, Seno H, Maeda T, Itoga M, Horiguchi J (2000a). Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome): 3 case reports [Letter]. Journal of Clinical Psychiatry 61, 299-300.
95. Nakajima M, Tanaka E, Kobayashi T, Ohashi N, Kume T, Yokoi T (2002). Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metabolism and Disposition 30, 636-642.
96. Olesen OV, Linnet K (1999). Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Therapeutic Drug Monitoring 21, 87-90.
97. Ozdemir V, Basile VS, Masellis M, Kennedy JL (2001). Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. Journal of Biochemistry and Biophysical Methods 47, 151-157.
98. Page RL, O'Neil MG, Yarbrough DR, Conradi S (1998). Fatal toxic epidermal necrolysis related to lamotrigene administration. Pharmacotherapy 18, 392-398.
99. Pan L, Belpaire FM (1999). In vitro study on the involvement of CYP1A2, CYP2D6, and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. European Journal of Clinical Pharmacology 55, 599-604.
100. Patel M, Tang BK, Grant DM, Kalow W (1995b). Interindividual variability in the glucuronidation of (S)-oxazepam contrasted with that of (R)-oxazepam. Pharmacogenetics 5, 287-297.
101. Patel M, Tang BK, Kalow W (1995a). (S) oxazepam glucuronidation is inhibited by ketoprofen and other UGT2B7 substrates. Pharmacogenetics 5, 43-49.
102. Perez-Stable EJ, Herrera B, Jacob P, Benowitz NL (1997), Nicotine metabolism and intake in black and white smokers. Journal of the American Medical Association 280, 152-156.
103. Perry PJ, Miller DD, Arndt S, Smith DA, Holman TL (1993). Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. Journal of Clinical Psychopharmacology 13, 46-51.
104. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM (1995). Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacology Bulletin 31, 327-331.
105. Raunio H, Rautio A, Gullstein H, Pelkonen O (2001). Polymorphism of CYP2A6 and its practical consequences. British Journal of Clinical Pharmacology 52, 357-363.
106. Rendic S, Di Carlo FJ (1997). Human cytochrome P-450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Review 29, 413-580.
107. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY (1999). Application of pharmacogenetics to psychotic disorders: the first consensus conference. Schizophrenia Research 37, 191-196.
108. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998). Meta-analysis of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8, 227-238.
109. Saitoh T, Xia Y, Chen Y (1995). The CYP2D6 mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Annals of Neurology 37, 110-112.
110. Samara EE, Granneman RG, Witt GF, Cavanaugh JH (1997). Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Journal of Clinical Pharmacology 37, 442-450.
111. Segman RH, Heresco-Levy U, Yakir A, Golster T, Strous R, Greenberg DA, Lerer B (2002). Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biological Psychiatry 51, 261-263.
112. Sharp S, Mak LY, Smith DJ, Coughtrie MW (1992). Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs - implications for adverse drug reactions. Xenobiotica 22, 13-25.
113. Shen WW (1997). The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biological Psychiatry 41, 814-826.
114. Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T, Takahashi (1995). Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 12, 323-333.
115. Shimoda K, Someya T, Morita S, Hirokane G, Noguchi T, Yokono A, Shibasaki M, Takhashi S (1999). Lower plasma levels of haloperidol in smoking than non-smoking schizophrenics. Therapeutic Drug Monitoring 21, 293-296.
116. Sonne J (1993). Factors and conditions affecting the glucuronidation of oxazepam. Pharmacology and Toxicology 73 (Suppl. 1), 1-23.
117. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997). Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. European Journal of Clinical Pharmacology 51, 395-398.
118. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, Manns MP (2000). Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. Journal of Biological Chemistry 275, 36164-71.
119. Strassburg CP, Nguyen N, Manns MP, Turkey RH (1998). Polymorphic expression of the UDP-glucuronosyl-transferase UGT1A gene locus in human gastric epithelium. Molecular Pharmacology 54, 647-654.
120. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP (2002). Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50, 259-265.
121. Tanner CM (1991). Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology 41 (Suppl. 2), 89-91.
122. Touw DJ (1997). Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabolism and Drug Interactions 14, 55-82.
123. Tukey RH, Strassburg CP (2000). Human UDP-glucuronosyltransferases: Metabolism, expression and disease. Annual Review of Pharmacology and Toxicology 40, 581-616.
124. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 42, 778-787.
125. Tyndale RF, Droll KP, Sellers EM (1997). Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7, 375-379.
126. Tyndale RF, Sellers EM (2002). Genetic variations in CYP2A6-mediated nicotine metabolism alter smoking behavior. Therapeutic Drug Monitoring 24, 163-173.
127. Walton K, Dorne JL, Renwick AG (2001). Uncertainty factors for chemical risks assessments: interspecies differences in glucuronidation. Food and Chemical Toxicology 39, 1175-1190.
128. Wang PC, Kuchel O, Buu NT, Genest J (1983). Catecholamine glucuronidation: an important metabolic pathway for dopamine in the rat. Journal of Neurochemistny 40, 1435-1440.
129. Watson SJ, Akil H (1999). Gene chips and arrays revealed: a primer on their power and their uses. Biological Psychiatry 45, 533-543.
130. Whalstrom A, Lenhammar L, Ask B, Rane A (1994). Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. Pharmacology and Toxicology 75, 23-27.
131. Wedlund PJ, de Leon J (2001). Pharmacogenetic testing: the cost factor. Pharmacogenomics Journal 1, 171-174.
132. Wright JH, Whitaker SB, Welch CB, Teller DN (1983). Hepatic enzyme induction patterns and phenothiazine side effects. Clinical Pharmacology and Therapeutics 34, 533-538.
133. Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO (2002). Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clinical Pharmacology and Therapeutics 72, 265-275.